Earnings Call Insights: Dyadic International (DYAI) Q1 2026 Management View “Over the last several years, we have worked to transform Dyadic from a platform technology company into a commercially focused biotechnology company capable of generating recurring revenues from products, partnerships, licensing opportunities and strategic collaborations,” said Joseph Hazelton (President & COO), adding, “...
Earnings Call Insights: Dyadic International (DYAI) Q1 2026 Management View “Over the last several years, we have worked to transform Dyadic from a platform technology company into a commercially focused biotechnology company capable of generating recurring revenues from products, partnerships, licensing opportunities and strategic collaborations,” said Joseph Hazelton (President & COO), adding, “products enabled by our microbial production platforms are now entering commercial channels.” Hazelton highlighted partner-driven launches as commercial validation: “Proliant Health & Biologics' commercial launch of Albufree Dx recombinant human albumin produced using Dyadic's platform technology” and “Inzymes has now commercialized recombinant non-animal bovine chymosin.” He also said, “Since these launches and partnership announcements, we've seen growing inbound interest from potential partners, distributors and customers.” On Life Sciences traction, Hazelton said, “During the quarter, we continued to expand customer engagement around recombinant bovine transferrin and received initial purchase orders within the cultivated meat segment,” and described channel expansion: “Another important milestone was our OEM distribution agreement with IBT Bioservices.” On Food & Nutrition timelines, Hazelton said of BRIG BIO’s alpha-lactalbumin program: “development work is underway, including product optimization and application testing with customer sampling currently expected to begin in mid-2026.” Mark Emalfarb (Founder, CEO & Director) positioned biopharma as partner-funded validation: “our biopharmaceutical activities continue to play an important strategic role by validating the capabilities of the C1 platform, generating non-dilutive funding and creating potential future licensing and partnership opportunities.” Ping Rawson (Chief Financial Officer) reported: “Total revenue for the 3 months ended March 31, 2026, was approximately $1.1 million,” and added, “We ended the first q...
Sapporo Holdings Ltd. suspended exports of its Pokka brand of beverages to the Middle East as escalating tensions involving Iran heighten concerns about demand. Rising raw material costs, including aluminum, reduced first-quarter profit by about ¥1 billion ($6.33 million), a company spokesperson said Thursday, although those pressures have so far been absorbed through price revisions. Pokka , Sapp...
Sapporo Holdings Ltd. suspended exports of its Pokka brand of beverages to the Middle East as escalating tensions involving Iran heighten concerns about demand. Rising raw material costs, including aluminum, reduced first-quarter profit by about ¥1 billion ($6.33 million), a company spokesperson said Thursday, although those pressures have so far been absorbed through price revisions. Pokka , Sapporo’s flagship soft-drinks brand, is central to its overseas beverages business, with a strong footprint in Southeast Asia and the Middle East. Its product line-up includes tea, coffee, and sports drinks. Sapporo expects shipments in the region to resume in October or later, though it cautioned that the outlook remains uncertain. With visibility limited, the brewer left its full-year guidance unchanged, maintaining its operating-income forecast of ¥6 billion, well below analyst expectations of ¥17.7 billion. The company noted that the Middle East situation had only a modest impact on its consolidated first-quarter results. Sapporo posted a net loss of ¥878 million for the quarter, narrowing from a ¥4.22 billion loss a year earlier. Shares fell as much as 12% in Tokyo on Thursday, the biggest drop since March 2011, following the earnings announcement. It closed the day 9.7% lower at ¥1516.5.